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Abstract
Aim To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID
pandemic.
Methods IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the
hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and
nucleoprotein, were used.
Results Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive)
as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days
after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
Conclusion The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization
support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
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Introduction
Coronavirus disease 2019 (COVID-19) is a severe acute re-
spiratory syndrome produced by a novel coronavirus (SARS-
CoV-2) that has spread globally and very quickly since its first
appearance in Wuhan, China, in December 2019 [1]. SARS-
CoV-2 is the seventh known coronavirus that infects humans;
SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause
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severe disease, whereas HKU1, NL63, OC43, and 229E are
associated with mild respiratory illness [2]. The virus has a
genome size of 30 kilobases that encodes multiple structural
and nonstructural proteins. The structural proteins include the
spike (S) protein, the envelope (E) protein, the membrane (M)
protein, and the nucleocapsid (N) protein.
The diagnostic approach to SARS-CoV-2 includes the de-
tection of viral RNA by real-time PCR (RT-PCR). Different
factors could contribute to false negative results of RNA tests
with RT-PCR, such as insufficient amount of virus at the site
of sample collection, incorrect sample collection or being out-
side in the viral replication time window [3–6]. Serological
methods combined with PCR could be of help for increasing
the sensitivity and accuracy of the diagnosis, especially in
patients with negative RT-PCR results; serology may also
help to identify asymptomatic and past infections. SARS-
COV-2 serology undoubtedly helps to understand the immune
status of the population and to evaluate viral spread [7]; hence,
serology should be used for epidemiological studies to inves-
tigate the rate of asymptomatic infections and to better esti-
matemorbidity andmortality [7]. Serological methods include
binding and neutralization assays. Binding assays such as
ELISAs are easily automatized, and they are verywell adapted
to a pandemic situation; neutralization assays require viral
culture, and they must be performed in a facilities with higher
biosecurity levels [8].
Preliminary studies have analyzed antibody responses
against SARS-COV-2. Some authors [2, 9–12] found that
IgM was detected on day 7 and peaked on day 28, and IgG
appeared by day 10 and peaked on day 49, while others [13]
determined that seroconversion among 173 patients took
place at median times of 12 (IgM), 14 (IgG), and 11 (neutral-
izing antibodies) days. The duration and nature of SARS-
CoV-2 immunity is unknown. The timescale of protection is
a critical determinant of the future impact of the pathogen. The
presence or absence of protective immunity due to infection or
vaccination (when available) will affect future transmission
and illness severity and will allow the identification of indi-
viduals with protective immunity [2, 7, 10, 13, 14].
Additional studies are needed to characterize how anti-
SARS-CoV-2 antibodies will change over prolonged periods
of time. The present study presents data from a large series of
samples covering both IgG and IgM + IgA responses to two of
the main viral antigenic proteins (N and S).
Materials and methods
Patients
One thousand two hundred thirty-six patients screened for
COVID-19 admitted to 18 Public and Private Spanish
Hospitals (Clínica Universidad de Navarra, Complejo
Asistencial Universitario de León, Complejo Hospitalario
Universitario de Albacete, Complejo Hospitalario de Jaén,
Hospital Clínico Universitario Lozano Blesa, Hospital
Clínico Universitario de Valladolid, Hospital Ramón y
Cajal, Hospital San Pedro, Hospital Universitario Clínico
San Cecilio, Hospital Universitario de Burgos, Hospital
Universi tar io Fundación Jiménez Díaz, Hospital
Universitario Juan Ramón Jiménez, Hospital Universitario
La Paz, Hospital Universitario Marqués de Valdecilla,
Hospital Universitario Miguel Servet, Hospital Universitario
Valle de Hebrón, Hospital Universitario Virgen de las Nieves,
and Hospital Universitario Virgen del Rocío) were studied.
All patients were positive by RT-PCR; sex data were available
for 513 men and 353 women; age data were available for 1066
patients, mean age 64 years, range 15–100 years.
Serum samples
Samples were drawn on the same day or after the RT-PCR test
was performed. Differences in days were due to clinical needs
in the general management of the patients.
Single serum samples were obtained from 1054 pa-
tients, while multiple serum samples (n = 413) were
obtained from 183 patients, comprising 1467 samples.
The distribution of samples according to time from
RT-PCR can be seen in Table 1. There were two sam-
ples available for 43 patients, the first collected before 4
days after PCR and the second collected 7–17 days
after PCR.
ELISAs
Anti-SARS-CoV-2 IgG and IgM + IgA ELISAs (Vircell SL,
Spain) were carried out according to the manufacturer’s pro-
tocol. Reaction wells in both assays were coated with nucleo-
capsid and spike proteins. Serum samples were previously
inactivated at 56 °C for 30 minutes. Samples were immediate-
ly tested after inactivation or stored at 4 °C for no longer than
4 days before testing. The specificity declared by the manu-
facturer for the IgG and IgM + IgA assays is 98.2% and
98.9%, respectively, based on studies performed on
prepandemic populations. Both ELISAs are qualitative; the
IgM + IgA ELISA does not differentiate between both
inmunoglobulins.
RT-PCR assays
RT-PCR from naso- and oro-pharyngeal swabs was per-
formed after nucleic acid extraction with different commercial
CE-approved assays.
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Statistical analysis
Statistical analysis was performed with the help of the R pro-
gram version 3.6.3 (2020-02-29)—“Holding the Windsock”
Copyright (C) 2020 The R Foundation for Statistical
Computing Platform: x86_64-w64-mingw32/x64 (64-bit).
Borderline results were primarily interpreted as negative.
The Wilcoxon-Mann-Whitney test was used for p-value cal-
culations. Data were graphically presented in box-and-
whisker plots with boxes encompassing 90% of the data and
whiskers presenting the 95% and 5% percentiles.
Results
Anti-SARS-CoV-2 antibody kinetics
The results from 1467 serum samples from PCR-positive pa-
tients referred to the collection date with respect to the first
PCR-positive result of the patient are shown in Table 1. At day
0, a higher reactivity was observed for IgM + IgA (154 pos-
itive samples, 47.2%) than for IgG (135, 41.4%), with 187
samples (57.4%) with any serological marker. This tendency
for a higher reactivity in the IgM + IgA response only reached
statistical significance at day 1 (p = 0.016), and could be seen
during the first 16 days, with 84.0% of IgM + IgA positive
results against 74.0% of IgG positive results at day 7 after
PCR. After the third week, the proportion of positive results
was similar in both parameters, while IgG was more prevalent
in samples collected onemonth after PCR. Positive IgM + IgA
together with positive IgG was the most frequently found
pattern (36.5%) at day 0, followed by positivity to only IgM
+ IgA (11.7%) and positivity to only IgG (5.8%). Throughout
all the time ranges studied and whenever a single marker was
present, IgM + IgA was more frequent than IgG.
Figure 1 shows the evolution of IgG and IgM + IgA over
time. The proportion of positive cases was higher for IgM + IgA
until day 24, when positivity for both IgG and IgM was equal.
To better understand the kinetics of the antibody response,
seroconversion was studied in 43 patients for whom two sam-
ples were available (T1: samples collected not later than 4
days post PCR; T2, second samples collected between 7 and
17 days post PCR). The results are shown in Table 2. IgG was
detected in 15 (34.9%) of the T1 samples, while IgM + IgA
was detected in 23 (53.5%). IgG and IgM + IgAwere detected
in 35 (81.4%) and 40 (93.0%) of the T2 samples, respectively.
Twenty patients seroconverted for IgG and 19 for IgM + IgA,
whereas 2 patients did not show seroconversion. The index
means were 1.97 (IgG) and 2.55 (IgM + IgA) for the acute
infection samples and 3.04 (IgG) and 3.15 (IgM + IgA) for the
convalescent samples.
Effect of age and sex on antibody responses to SARS-
CoV-2
PCR-positive patients were classified into four groups accord-
ing to the results of the serological tests: only IgG positive,
only IgM + IgA positive, positive in both tests or negative in
both tests. Figure 2a shows the distribution of serological re-
sults by age group corresponding to the 1066 patients for
Table 1 Positive rates for IgG and IgA + IgM detection in 1466 serum samples from PCR-positive patients. The results are expressed as absolute
frequencies (percentage shown in parentheses) of positive samples in each parameter or in both parameters at the same time
Sample daya Total no.
of sera
IgG IgM + IgA IgG and/or
IgM + IgA
Only IgG positive Only IgM
+ IgA positive
Both IgG and IgM
+ IgA positive
Both IgG and IgM
+ IgA negative
0 326 135 (41.4) 154 (47.2) 187 (57.4) 19 (5.8) 38 (11.7) 116 (35.6) 153 (46.9)
1 332 134 (40.4) 165 (49.7)b 180 (54.2) 21 (6.3) 52 (15.7) 113 (34.0) 146 (44.0)
2 154 83 (53.9) 98 (63.6) 95 (61.7) 6 (3.9) 21 (13.6) 77 (50.0) 50 (32.5)
3 106 61 (57.5) 68 (64.2) 69 (65.1) 8 (7.5) 15 (14.2) 53 (50.0) 30 (28.3)
4 111 79 (71.2) 89 (80.2) 92 (82.9) 7 (6.3) 17 (15.3) 72 (64.9) 15 (13.5)
5 51 40 (78.4) 42 (82.4) 39 (76.5) 2 (3.9) 4 (7.8) 38 (74.5) 7 (13.7)
6 53 34 (64.2) 38 (71.7) 38 (71.7) 1 (1.9) 5 (9.4) 33 (62.3) 14 (26.4)
7 50 37 (74.0) 42 (84.0) 41 (82.0) 1 (2.0) 6 (12.0) 36 (72.0) 7 (14.0)
8 42 26 (61.9) 33 (78.6) 32 (76.2) 1 (2.4) 8 (19.0) 25 (59.5) 8 (19.0)
9 30 20 (66.7) 23 (76.7) 23 (76.7) 1 (3.3) 4 (13.3) 19 (63.3) 6 (20.0)
10–16 129 114 (88.4) 119 (92.2) 118 (91.5) 2 (1.6) 7 (5.4) 112 (86.8) 8 (6.2)
17–23 40 36 (90.0) 36 (90.0) 38 (95.0) 1 (2.5) 1 (2.5) 35 (87.5) 3 (7.5)
24–30 16 16 (100) 16 (100) 16 (100) 0 (0.0) 0 (0.0) 16 (100) 0 (0.0)
> 30 26 24 (92.3) 20 (76.9) 24 (92.3) 4 (15.4) 0 (0.0) 20 (76.9) 2 (7.7)
a Days after the first positive PCR result
b p = 0.016 compared to IgG (all other comparisons not significative)
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whom age data were available. The proportion of patients with
negative serological responses for both tests increased with
patient age. When these results were analyzed according to
the time elapsed between the PCR and the serum collection
(Fig. 2b and c), this effect could also be seen for samples
collected early after the first PCR diagnosis, while most sam-
ples collected in the second week after PCR showed positive
serological responses in all age groups.
Figure 3 shows the differences in serological results by age
and sex. No significant differences were seen between men
and women as a whole either for IgG or for IgM + IgA.
Although differences between the sexes could be observed
for some age groups, there was not a clear tendency that sup-
ported a higher serological response of men over women, and
this result may reflect differences in the population sizes.
Discussion
The utility of serological tests to help in the diagnosis of
COVID-19 was evaluated in a multicenter study with a large
series of samples collected from 1236 patients in several
Spanish hospitals during the peak of the pandemic. In our
study, we observed high values of sensitivity, especially for
the IgM + IgA test at early periods of time after hospitalization
(61.7% presented a positive serology in the first 4 days of the
diagnosis, and 90.5% after the first week). We believe that our
findings support the use of serological assays as supplemen-
tary diagnostic tests for the clinical management of COVID-
19. We also observed a decreased sensitivity of serology in
older patients in samples collected early in the disease.
Two commercial kits were used to measure the IgG
and IgM + IgA responses against two major antigenic
components of the virus, the N and S proteins. To our
knowledge, few commercial tests are simultaneously
based on both proteins. Studies with good performances
for assays based either on the N protein [15, 16], the S
protein [7, 13, 17] or both antigens [9, 10, 14, 18] have
been published. Another peculiarity of the assays used in
the study is the inclusion of IgA together with IgM for
early detection of the disease. Several studies have de-
scribed a good sensitivity of this immunoglobulin class,
better than that of IgG, although with a lower specificity
[2, 7, 12, 18, 19]. The specificity of the test was
established by the manufacturer of the kit on the basis
of samples collected from prepandemic populations
(98.8% CI 95% 95.52–99.68). The high levels of sensi-
tivity reported in the present study, above those reported
in other studies [17, 20, 21], may be related to the afore-
mentioned special features of the assays used in the study:
the use of two viral antigens and the inclusion of IgA.
The percentage of IgM + IgA-positive patients with IgG-
negative levels was higher in samples collected at early stages
of the disease, as can be expected for these immunoglobulin
classes. However, we did not observe a decrease in IgM + IgA
values, as has been shown by other authors [9], probably due
to the low number of samples after hospital discharge included
in the study. Positivity of the serological tests increases with
time, reaching values close to 100% in samples taken 10 days
or more after the first PCR result. Conversely, in studies car-
ried out withMERS patients, 20% of the patients did not show
Fig. 1 Dynamic trend of the
positive rate for IgG and IgM +
IgA in sera of RT-PCR-positive
patients
Table 2 Positive rates for IgG and IgA + IgM detection in sera from
selected patients for whom two samples collected at two different time
points were available. Time ranges were 0–4 days post PCR for first
serum collection and 7–17 days post PCR for second serum collection
Serological parameter No. of positive sera (%)
0–4 days 7–17 days
IgG 15 (34.9) 35 (81.4)
IgM + IgA 23 (53.5) 40 (93.0)
Both IgG and IgM + IgA 15 (34.9) 34 (79.1)
IgG only 1 (2.3) 1 (2.3)
IgM + IgA only 8 (18.6) 6 (14.0)
Both negative 19 (44.2) 2 (4.7)
T1 first serum, T2 second serum
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a detectable serological response after more than 30 days of
evolution [22]. For SARS, all patients developed antibodies
[23], but 28% showed negative IgM after 60 days [24], and
most patients had lost the antibody response by six years [25].
However, it is surprising that the large proportion of pa-
tients with positive IgG levels in samples were surveyed so
close to the first PCR-positive results: 45.0% within the first 3
days. Some of the patients even debuted with an IgG-positive/
IgM + IgA-negative pattern. This finding could be in agree-
ment with previous contact with other coronaviruses showing
antigenic similarities with the novel SARS-CoV-2, as has
been found by authors studying immune cell responses [26],
and it could also be explained by the fact that patients are
attending the emergency room and need hospitalization, sug-
gesting advanced disease. However, it is not in agreement
with the very low levels of IgG against the spike protein and
Fig. 2 Serology test results for positive PCR patients grouped by age. Bar
heights represent absolute frequencies. a Data from all PCR-positive pa-
tients, b results corresponding to samples collected in the first week after
the first PCR result, and c results corresponding to samples collected later
than one week after the first PCR result
Fig. 3 IgG and IgM + IgA index value (10 X serum/cutoff) boxplot for all PCR-positive patients distinguishing between male and female and grouped
by age. Boxes encompass 90% of the data, and whiskers present the 95% and 5% percentiles
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nucleoprotein found in the prepandemic population that trans-
lates to the very high specificity of the serological assays used
in this and other studies [27].
Due to the large series of sera studied, serological results
could be stratified according to the age of the patients. A
decreased number of patients with positive serology was ob-
served among the older patients for samples collected early in
the disease. However, the proportion increased to near 100%
positivity in all age groups for samples collected in the second
week or later after the first positive PCR result. Some authors
have suggested a relationship between this delayed response
in elderly individuals, with less favorable disease evolution in
this population group [28]. For the comparison of serological
responses between men and women, no global significant
differences were observed either in the proportion of positive
results or in the immunoglobulin levels attained in each group.
The low number of samples in some of the subgroups may
have limited the statistical potency of the comparisons.
In summary, the high values of sensitivity attained in the
present study from a relatively early period of time after hos-
pitalization support the use of the evaluated serological assays
as supplementary diagnostic tests for the clinical management
of COVID-19. The large number of samples gives a particular
strength to the evaluation compared with that of others previ-
ously published. However, the lack of clinical and evolution-
ary data of the patients, as well as having used time from
positive PCR result rather than time from symptom onset,
constitutes its major limitations.
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